Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial

INTRODUCTION: EndoPredict (EP) is an RNA-based multigene test that predicts the likelihood of distant recurrence in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) breast cancer (BC) who are being treated with adjuvant endocrine therapy. Here...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Martin, Miguel, Brase, Jan C, Calvo, Lourdes, Krappmann, Kristin, Ruiz-Borrego, Manuel, Fisch, Karin, Ruiz, Amparo, Weber, Karsten E, Munarriz, Blanca, Petry, Christoph, Rodriguez, Cesar A, Kronenwett, Ralf, Crespo, Carmen, Alba, Emilio, Carrasco, Eva, Casas, Maribel, Caballero, Rosalia, Rodriguez-Lescure, Alvaro
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2014
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4076639/
https://ncbi.nlm.nih.gov/pubmed/24725534
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3642
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים